Tumor reversion is the biological process by which highly tumorigenic cells lose at great extent or entirely their malignant phenotype. In this context, partner 10 (A. Telerman and R. Amson) established biological models of reversion, which was done by deriving revertant cells from different tumors. Additionally, they showed that TPT1/TCTP is the most strongly downregulated protein in the revertant cells compared with the parental cancer cells. They demonstrated that decreasing the expression of TPT1/TCTP results in either apoptosis or reprogramming of cancer cells into revertants.
Through a pluridisciplinary programm (Medicinal Chemistry, Molecular Modeling and Biology) involving partners 10 and 15, the purpose of our research is to understand the molecular program of tumor reversion and its clinical application.
.